Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer
Open Access
- 16 October 2001
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 85 (8) , 1106-1112
Abstract
The association between tumour shrinkage and reduction in kinetic cell activity after primary chemotherapy in human breast cancer is still a matter of investigation. 157 patients with T2-4, N0-1, M0 breast cancer received primary chemotherapy consisting of either the CMF regimen + tamoxifen (the first consecutive 76 cases) or the single agent epirubicin (the subsequent 81). Ki67, p53, bcl2, c-erbB2 and steroid hormone receptors were evaluated immunohistochemically in tumour specimens obtained before chemotherapy and at surgery. Tumour shrinkage of >50% occurred in 72.4% of patients. Ki67 expression significantly decreased after chemotherapy; the reduction correlated with tumour response in both univariate (P < 0.005) and multivariate analysis (P = 0.02). p53, bcl-2, steroid hormone receptor and c-erbB2 immunostaining were scarcely affected. Baseline bcl2 (P = 0.04) and c-erbB2 (P = 0.02) were directly and inversely associated with the reduction in Ki67 immunostaining, respectively. Baseline p53 expression (P < 0.01) was directly related with Ki67 expression at residual tumour, whereas oestrogen receptor expression (P < 0.001) was inversely related. Ki67 at residual tumour was a better predictor for relapse-free survival (RFS) than baseline Ki67. Clinical response (P < 0.03), but not reduction in Ki67, was a significant independent predictor for disease recurrence. Chemotherapy was found to induce tumour shrinkage and to reduce the number of cells in the cell cycle, but its effect on tumour biology/aggressiveness was minimal. Reduction in Ki67 immunostaining correlated with clinical response but failed to be related to RFS. Ki67 expression at surgery rather than at baseline appears to be a better predictor for disease relapse. © 2001 Cancer Research Campaign http://www.bjcancer.comKeywords
This publication has 24 references indexed in Scilit:
- p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.2000
- The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2Annals of Oncology, 2000
- Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast CancerJournal of Clinical Oncology, 1999
- A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancerAnnals of Oncology, 1998
- Her-2/neu as a Predictive Marker of Response to Breast Cancer TherapyBreast Cancer Research and Treatment, 1998
- Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinomaBreast Cancer Research and Treatment, 1996
- Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-upEuropean Journal of Cancer, 1992
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- Changes in cell kinetics induced by primary chemotherapy in breast cancerInternational Journal of Cancer, 1991
- Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or MoreJNCI: Journal of the National Cancer Institute, 1990